Adult Patient with Pseudo-Resistant Hypertension: Low Adherence

  • Massimo Salvetti
Part of the Practical Case Studies in Hypertension Management book series (PCSHM)


There is clear evidence that BP-lowering strategies substantially reduce cardiovascular risk. Despite this, studies performed in several countries show that in a noticeable proportion of treated hypertensive patients, BP control is seldom obtained. It is important to keep in mind that uncontrolled hypertension does not mean “resistant” hypertension: pseudoresistance is not uncommon in everyday practice. Poor adherence to treatment is frequently responsible for inadequate BP control and should be sought carefully. Investigating adherence to treatment, however, is very difficult, and in most cases physicians tend to overestimate patient’s adherence to treatment. This clinical case describes a patient referred for resistant hypertension; careful evaluation excluded secondary forms of hypertension such as primary aldosteronism or renovascular hypertension. Blood pressure target was reached after treatment simplification and education of the patient.


Blood Pressure Control Antihypertensive Treatment Ambulatory Blood Pressure Monitoring Primary Aldosteronism Renovascular Hypertension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.CrossRefPubMedGoogle Scholar
  2. 2.
    Reboldi G, Angeli F, Verdecchia P. Ambulatory blood pressure profile for risk stratification. Keep it simple. Hypertension. 2014;63:913–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2014;2(8):634–47.CrossRefGoogle Scholar
  4. 4.
    Tocci G, Ferrucci A, Pontremoli R, Ferri C, Agabiti Rosei E, Morganti A, Trimarco B, Mancia G, Borghi C, Volpe M. Blood pressure levels and control in Italy: comprehensive analysis of clinical data from 2000–2005 and 2005–2011 hypertension surveys. J Hum Hypertens. 2015;29(11):696–701.CrossRefPubMedGoogle Scholar
  5. 5.
    Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly treated patients: a population-based study in Italy. J Hypertens. 2008;26(4):819–24.CrossRefPubMedGoogle Scholar
  6. 6.
    Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28(7):1584–90.CrossRefPubMedGoogle Scholar
  7. 7.
    Mancia G, Omboni S, Grassi G. Combination treatment in hypertension: the VeraTran Study. Am J Hypertens. 1997;10(7 Pt 2):153S–8S.PubMedGoogle Scholar
  8. 8.
    Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399–407.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Massimo Salvetti
    • 1
  1. 1.ASST Spedali Civili di BresciaClinica Medica-University of BresciaBresciaItaly

Personalised recommendations